These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8445951)

  • 1. Response of therapy-related myelodysplasia to low-dose interleukin-2.
    Toze CL; Barnett MJ; Klingemann HG
    Leukemia; 1993 Mar; 7(3):463-5. PubMed ID: 8445951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
    Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI
    Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
    Ogata K; Yokose N; Nomura T
    Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of short-course, high-dose steroid therapy in a child with myelodysplastic syndrome.
    Hiçsönmez G; Tunç B; Olcay L; Tuncer MA
    Pediatr Hematol Oncol; 2001 Dec; 18(8):525-9. PubMed ID: 11764102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
    Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
    Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of recombinant alpha-interferon administration on peripheral blood lymphocyte subpopulations and natural killer cell activity in patients with refractory anemia with excess of blasts.
    Eliopoulos G; Coulocheri S; Vaiopoulos G; Alexandrakis M; Ganotakis E; Eliopoulos A; Yataganas X
    Nouv Rev Fr Hematol (1978); 1991; 33(1):21-4. PubMed ID: 1945821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
    Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
    Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
    Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
    Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
    Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
    Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells.
    Galvani DW; Nethersell AB; Cawley JC
    Leuk Res; 1988; 12(3):257-62. PubMed ID: 3163399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
    Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.